Taro Pharmaceuticals (United States)

Patients with Demodex blepharitis have a considerable symptomatic burden that negatively impacts their daily activities and well-being. Despite chronic manifestations of and problems associated with blepharitis that resulted in multiple visits to eye care providers, Demodex blepharitis remained underdiagnosed or misdiagnosed. This study aimed to evaluate the effect of Demodex blepharitis on patients' daily activities and well-being. This prospective, multicenter, observational study recruited 524 patients with Demodex blepharitis from 20 U.S. ophthalmology and optometry practices. Demodex blepharitis was diagnosed based on the presence of the following clinical manifestations in at least one eye: >10 collarettes on the upper lashes, at least mild lid margin erythema of the upper eyelid, and mite density of ≥1.0 mite/lash (upper and lower combined). Patients were asked to complete a questionnaire related to their symptoms, daily activities, and management approaches. The proportion of patients who experienced blepharitis symptoms for ≥2 years was 67.8%, and for ≥4 years, it was 46.5%. The three most bothersome symptoms ranked were "itchy eyes," "dry eyes," and "foreign body sensation." Overall, 77.4% of patients reported that Demodex blepharitis negatively affected their daily life. One-third (32.3%) of patients had visited a doctor for blepharitis at least two times, including 19.6% who visited at least four times. Despite having clinical manifestations of Demodex blepharitis confirmed by an eye care provider, 58.7% had never been diagnosed with blepharitis. Commonly used management approaches were artificial tears, warm compresses, and lid wipes. Among those who discontinued their regimen, 45.9% had discontinued because of either tolerability issues or lack of effectiveness. Among contact lens wearers, 64.3% of the patients either were uncomfortable wearing contact lenses or experienced vision changes "sometimes" or "frequently." Demodex blepharitis results in a significant negative impact on daily activities, creating a psychosocial and symptomatic burden on patients.

This paper aims at calculating the number of required classrooms of each subject in a junior high school corresponding to the new educational guidelines. In calculation of the number of required classrooms, it analyzed by collecting the timetables of 40 schools in Tokyo. Furthermore, based on the calculated number of required classrooms, the rate of classroom use of each subject was calculated. Consequently, when saying from the field of the rate of classroom use, it became clear about a departmental system being effective also in subject classroom type management. I think that these analysis results are important when considering a future junior high school architectural planning.

In this paper, the high-fluidity concrete placing into the wall form with the obstructions is simulated in order to confirm that this 3-D flow simulation system can be applied to full-sized structure. In the beginning, the parametric studies are carried out about the handling between the form and fresh concrete on the touching side, and the rheology constants on the fluid surface are examined. As a result, the experiment is simulated by correcting the rheology constant of the surface material, multiplying the rate of VOF(volume of fluid) and decreasing to 1/2. Next, the parametric studies are executed about the rheology constants and the amount of obstructions in the wall form by this decrease method. As a result, it is clarified that this 3-D flow simulation system can correctly express the influence by the rheology constants and the amount of obstructions.

The FDA recently issued a guidance covering practices of scaleup and post approval changes with semisolids (SUPAC-SS). This guidance outlines the steps that must be taken by a company to maintain certification of its semisolid dermatological products after quantitative changes have been made in their compositions and/or after changes have been made in the sourcing of their key ingredients, in their processing, in their batch sizes, and/or after their site of manufacture has been relocated. A key element within the guidance is a release test to be used to determine if the diffusional release of a drug found in a formulation is the same after changes have been made to the formulation as it was prior to implementing the changes. The AAPS-FDA sponsored workshop was set up to explore this qualifying test. The stated aims of the workshop were: a) to illustrate the methodology and techniques of in vitro release testing, b) to show the sensitivity of in vitro release with respect to manufacturing variables and to variations in components and composition (of specific formulations), c) to recognize in vitro release testing as a useful procedure for SUPAC documentation, d) to highlight and evaluate other applications of in vitro release testing, e) to explore the degree to which in vitro release testing and bioavailability may be related, and f) to evaluate the role of in vitro release testing of topical dosage forms as a tool to improve product quality.

The erythropoietin (EPO) response to anemia was assessed for 244 subjects aged 1-64 years (mean 45.2 years) and 121 subjects aged 65-94 years (mean 68.3 years). Subjects included non-anemic individuals as well as those with anemia of various etiologies, excluding renal disease and pregnancy. Significant inverse correlations between serum immunoreactive EPO and hematocrit were noted for both groups. Regression lines failed to show a significantly lower slope or y-intercept for older compared to younger subjects. EPO levels were not significantly lower for older compared to younger subjects when controlled for hematocrit level. These results suggest that the EPO response to anemia in older subjects is similar to that of younger subjects.

ABSTRACT Vaginal antifertility agents are an important part of the overall contraceptive armamentarium. Maximum effort should be placed on programs to improve their present status with regard to their contraceptive efficacy, ease of administration and general aesthetic acceptability. Initial testing for spermicides has been dependent on a series of in vitro screening methods incorporating human sperm with spermicides and utilizing immobility or sperm death as the end point. Confusion has existed in interpretation of results using different test systems. The International Planned Parenthood Foundation Agreed Test for Total Spermicide Power is now being used in most laboratories as the standard screening method. The test does not detect acrosomal proteinase inhibitors which may be useful vaginal antifertility agents. New screening methods must be developed. Vaginal irritation has been assessed in the dog, monkey and rabbit. It is suggested that the ten day rabbit vaginal irritation study be used as an additional standard method to establish tolerances for new vaginal antifertility agents. Toxicity studies have ranged from 30 to 180 days and have been conducted in rabbits, dogs and monkeys. Additional animal studies may be necessary to assess teratogenicity and carcinogenicity. As new vaginal antifertility agents are developed, new means of assessing their activity must be developed. The frog and rabbit models described will be of value as additional screening methods.